C4 Therapeutics, Inc.
CCCC · NASDAQ Global Select · USD
3,15USD
+0,05 (+1,61 %)Stand 9. Nov., 21:00
Nachbörslich3,11−0,04 (−1,27 %)19:30 ET
Kennzahlen
- Eröffnung
- 3,13
- Vortag
- 3,10
- Tagesspanne
- 3,04 – 3,225
- 52 Wochen
- 1,69 – 5,17
- Volumen
- 2,39 Mio.
- Ø Volumen
- 2,6 Mio.
- Börsenwert
- 387,53 Mio. $
- KGV
- -4,4
- Gewinn je Aktie (TTM)
- -0,72
- Dividendenrendite
- 0,0 %
- Beta
- 3,2
- Nächste Zahlen
- 25. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 35,95 Mio. | 35,58 Mio. | 20,76 Mio. | 31,1 Mio. | 45,79 Mio. |
| Herstellungskosten | 7,98 Mio. | 0 | 7,74 Mio. | 0 | 0 |
| Bruttogewinn | 27,97 Mio. | 35,58 Mio. | 13,02 Mio. | 31,1 Mio. | 45,79 Mio. |
| Forschung und Entwicklung | 104,24 Mio. | 110,64 Mio. | 117,71 Mio. | 117,84 Mio. | 94,67 Mio. |
| Vertrieb und Verwaltung | 36,2 Mio. | 42,12 Mio. | 42,08 Mio. | 42,79 Mio. | 33,25 Mio. |
| Operatives Ergebnis | −104,49 Mio. | −119,61 Mio. | −139,03 Mio. | −129,53 Mio. | −82,13 Mio. |
| EBITDA | −102,91 Mio. | −103,37 Mio. | −127,96 Mio. | −124,28 Mio. | −80,26 Mio. |
| Nettogewinn | −104,99 Mio. | −105,32 Mio. | −132,49 Mio. | −128,18 Mio. | −83,89 Mio. |
| Gewinn je Aktie (verwässert) | -1,27 | -1,52 | -2,67 | -2,62 | -1,82 |
Bewertung
Letzte 12 Monate
- KGV
- -4,4
- Kurs-Umsatz-Verhältnis
- 12,0
- Kurs-Buchwert-Verhältnis
- 1,9
- PEG
- -0,0
- Bruttomarge
- 94,4 %
- Operative Marge
- −315,9 %
- Nettomarge
- −282,2 %
- Verschuldungsgrad
- 0,2
- EV/EBITDA
- -4,4
- Eigenkapitalrendite
- −37,7 %
- Kapitalrendite (ROIC)
- −34,3 %
- Free-Cashflow-Rendite
- −20,6 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 77,8 % | 100,0 % | 62,7 % | 100,0 % | 100,0 % |
| Operative Marge | −290,7 % | −336,1 % | −669,8 % | −416,6 % | −179,4 % |
| Nettomarge | −292,1 % | −296,0 % | −638,3 % | −412,2 % | −183,2 % |
| KGV | -1,5 | -2,4 | -2,1 | -2,3 | -17,7 |
| Kurs-Umsatz-Verhältnis | 4,4 | 7,0 | 13,5 | 9,3 | 32,4 |
| Kurs-Buchwert-Verhältnis | 0,6 | 1,2 | 1,1 | 1,0 | 3,8 |
| Verschuldungsgrad | 0,2 | 0,3 | 0,3 | 0,3 | 0,1 |
| Liquidität 3. Grades | 7,8 | 5,7 | 6,3 | 6,5 | 6,4 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 143,71 Mio. | 260 Mio. | 224,85 Mio. | 345,68 Mio. | 1,45 Mrd. |
| EV/EBITDA | -1,4 | -2,5 | -1,8 | -2,8 | -18,1 |
| Eigenkapitalrendite | −40,9 % | −48,8 % | −53,8 % | −44,3 % | −21,5 % |
| Kapitalrendite (ROIC) | −31,4 % | −38,6 % | −41,0 % | −32,9 % | −18,0 % |
| Free-Cashflow-Rendite | −62,7 % | −26,2 % | −38,7 % | −38,7 % | −6,0 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +1,0 % | +71,4 % | −33,3 % | −32,1 % | +37,9 % |
| Bruttogewinn | −21,4 % | +173,3 % | −58,1 % | −32,1 % | +201,2 % |
| Operatives Ergebnis | +12,6 % | +14,0 % | −7,3 % | −57,7 % | −35,9 % |
| Nettogewinn | +0,3 % | +20,5 % | −3,4 % | −52,8 % | −26,5 % |
| Gewinn je Aktie | +16,4 % | +43,1 % | −1,9 % | −44,0 % | −18,2 % |
| Freier Cashflow | −52,0 % | +39,8 % | +2,6 % | −26,3 % | −30,0 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 11Kaufen
- 3Halten
- 1Verkaufen
- 0Stark verkaufen
Kursziel
11,33
Durchschnitt · +259,68 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 26,33 Mio. | 22,43 Mio. | 19,15 Mio. |
| Umsatz (Tief – Hoch) | 20,85 Mio. – 32,14 Mio. | 21,94 Mio. – 22,91 Mio. | 19,08 Mio. – 19,21 Mio. |
| Gewinn je Aktie (Ø) | -0,84 | -0,92 | -1,09 |
| Gewinn je Aktie (Tief – Hoch) | -0,93 – -0,77 | -1,06 – -0,79 | -1,69 – -0,79 |
| Analysten | 5 | 6 | 7 |
Letzte Änderungen
- Guggenheim6. Nov. 2026Buy
- Evercore ISI Group1. Juni 2026Outperform
- Barclays27. Feb. 2026Overweight
- Brookline Capital23. Feb. 2026Buy
- Barclays17. Dez. 2025Overweight
- Wells Fargo23. Sept. 2025Overweight
- Barclays23. Sept. 2025Overweight
- Stephens & Co.22. Sept. 2025Overweight
Quartalszahlen
Nächste Zahlen: 25. Feb. 2027| Nov. 2026 | Aug. 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | -0,19 | -0,23 | -0,25 | -0,31 | -0,41 | -0,38 | -0,48 | -0,45 |
| Gewinn je Aktie · Tatsächlich | -0,16 | -0,18 | -0,20 | -0,18 | -0,44 | -0,37 | -0,37 | -0,49 |
| Abweichung | +17,74 % | +20,49 % | +20,20 % | +41,94 % | −8,45 % | +2,63 % | +22,92 % | −8,89 % |
| Umsatz · Tatsächlich | 8,47 Mio. | 6,64 Mio. | 6,2 Mio. | 11,02 Mio. | 11,2 Mio. | 6,46 Mio. | 7,2 Mio. | 5,18 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 93,98 %
- Investoren mit 13F-Meldung
- 158
Größte Investoren
- MORGAN STANLEY6,78 %8,87 Mio.
- RA CAPITAL MANAGEMENT, L.P.6,12 %8 Mio.
- BLACKROCK, INC.6,04 %7,9 Mio.
- LYNX1 CAPITAL MANAGEMENT LP5,61 %7,33 Mio.
- SQUADRON CAPITAL MANAGEMENT LLC5,51 %7,2 Mio.
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC5,49 %7,17 Mio.
- JPMORGAN CHASE & CO3,63 %4,75 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC3,38 %4,42 Mio.
Insider-Geschäfte
- Anderson Kenneth Carl1. Okt. 2026 · directorKauf3662 Aktien · 3,14
- GROGAN DONNA ROY1. Okt. 2026 · directorKauf4618 Aktien · 3,14
- Adams Kendra18. Sept. 2026 · officer: Chief Financial OfficerKauf6250 Aktien
- Adams Kendra18. Sept. 2026 · officer: Chief Financial OfficerVerkauf2775 Aktien · 3,39
- REYNO LEONARD10. Juli 2026 · officer: Chief Medical OfficerKauf15.325 Aktien
- REYNO LEONARD10. Juli 2026 · officer: Chief Medical OfficerVerkauf7397 Aktien · 4,06
- Anderson Kenneth Carl1. Juli 2026 · directorKauf2650 Aktien · 4,34
- GROGAN DONNA ROY1. Juli 2026 · directorKauf3341 Aktien · 4,34
Vergleichbare Unternehmen
Über das Unternehmen
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
Führung
- Andrew J. HirschChief Executive Officer, President & Director
- Leonard J. ReynoChief Medical Officer
- Kendra AdamsPrincipal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer
- Kenneth C. AndersonCo-Founder, Independent Director & Member of Scientific Advisory Board
- Christopher NasveschukSenior Vice President of Chemistry
- Isabel ChiuSenior Vice President of Strategic Alliances & Business Development
- CEO
- Andrew J. Hirsch
- Mitarbeitende
- 104
- Hauptsitz
- Watertown, MA, US
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 2. Okt. 2020
- Website
- c4therapeutics.com
Nachrichten
- Zacks Investment Research · 5. Nov., 10:36C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates
- GlobeNewsWire · 5. Nov., 7:00C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- GlobeNewsWire · 3. Nov., 7:00C4 Therapeutics to Participate in Upcoming November Investor Conferences
- GlobeNewsWire · 2. Nov., 16:01C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Zacks Investment Research · 29. Okt., 11:06C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- GlobeNewsWire · 29. Okt., 7:00C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
- Defense World · 22. Okt., 2:45Tenaya Therapeutics (NASDAQ:TNYA) and C4 Therapeutics (NASDAQ:CCCC) Financial Survey
- PRNewsWire · 20. Okt., 7:00Insmed Appoints Two New Directors to Its Board
- Defense World · 12. Okt., 2:15Reviewing ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)
- GlobeNewsWire · 25. Sept., 7:00C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.